Mural Oncology Reports Shareholder Approval for Acquisition by XRA 5 Corp., a Subsidiary of XOMA Royalty

Acquisition Approval: Mural Oncology plc's shareholders have approved the acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, with over 99% of votes in favor during meetings held on October 24, 2025.

Transaction Details: The acquisition values Mural at approximately $36.2 million, with shareholders set to receive a base cash price of $2.035 per share, plus a potential additional cash amount based on Mural's closing net cash.

Voting Results: At the Scheme Meeting, 99.20% of votes were in favor of the acquisition proposal, while the Extraordinary General Meeting also saw overwhelming support, with 99.16% approval for the scheme of arrangement.

Future Steps: The acquisition is expected to close in the fourth quarter of 2025, pending customary closing conditions and approval from the High Court of Ireland.